$SPHS: is going up fast: Sophiris Bio Inc. (NAS
Post# of 23113
Posted On: 05/06/2016 9:45:28 AM
$SPHS: is going up fast:
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced that positive data from its Phase 3 study of topsalysin as a treatment for the symptoms of benign prostatic hyperplasia will be presented as a late breaking poster on May 7, 2016 from 4:00 p.m. to 5:30 p.m. pacific time in the Science and Technology Hall at the 111th American Urological Association Annual Meeting.
Abstract No. 16-8385 (LB-S&T-04): "Prospective, Randomized, Double Blind, Vehicle Controlled, Multinational, Phase 3 Clinical Trial of the Pore Forming Protein PRX302 for Targeted Treatment of Symptomatic Benign Prostatic Hyperplasia (The PLUS-1 Trial)" Presenting Author: Dr. Claus Roehrborn, UT Southwestern Medical Center Poster Session: Late-Breaking Science & Technology Poster Time: May 7, 2016 from 4:00 p.m. to 5:30 p.m. pacific time
The abstract related to the poster can be accessed through the American Urological Association website at http://www.aua2016.org/abstracts/.
About Sophiris
Sophiris Bio Inc. is a biopharmaceutical company developing topsalysin, a clinical-stage, targeted therapy for the treatment of urological diseases. Topsalysin is in Phase 3 clinical development for the treatment of the symptoms of benign prostatic hyperplasia (BPH) and is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Topsalysin is also currently in a Phase 2a proof of concept study for the treatment of localized low to intermediate risk prostate cancer. For more information, please visit www.sophirisbio.com.
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
, a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced that positive data from its Phase 3 study of topsalysin as a treatment for the symptoms of benign prostatic hyperplasia will be presented as a late breaking poster on May 7, 2016 from 4:00 p.m. to 5:30 p.m. pacific time in the Science and Technology Hall at the 111th American Urological Association Annual Meeting. Abstract No. 16-8385 (LB-S&T-04): "Prospective, Randomized, Double Blind, Vehicle Controlled, Multinational, Phase 3 Clinical Trial of the Pore Forming Protein PRX302 for Targeted Treatment of Symptomatic Benign Prostatic Hyperplasia (The PLUS-1 Trial)" Presenting Author: Dr. Claus Roehrborn, UT Southwestern Medical Center Poster Session: Late-Breaking Science & Technology Poster Time: May 7, 2016 from 4:00 p.m. to 5:30 p.m. pacific time
The abstract related to the poster can be accessed through the American Urological Association website at http://www.aua2016.org/abstracts/.
About Sophiris
Sophiris Bio Inc. is a biopharmaceutical company developing topsalysin, a clinical-stage, targeted therapy for the treatment of urological diseases. Topsalysin is in Phase 3 clinical development for the treatment of the symptoms of benign prostatic hyperplasia (BPH) and is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Topsalysin is also currently in a Phase 2a proof of concept study for the treatment of localized low to intermediate risk prostate cancer. For more information, please visit www.sophirisbio.com.
(1)
(0)